{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:07:48Z","timestamp":1790654868996,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019871","name":"Castle Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CorEvitas"},{"name":"Dermavant"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mindera"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arcutis"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leo"},{"name":"Lilly"},{"name":"Sun"},{"name":"UCB"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-022-02510-4","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T17:05:58Z","timestamp":1670864758000},"page":"1793-1796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ethnoracial representation in hidradenitis suppurativa clinical trials"],"prefix":"10.1007","volume":"315","author":[{"given":"Kareem G.","family":"Elhage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley K.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Q.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Yeroushalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"2510_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","volume":"318","author":"DML Saunte","year":"2017","unstructured":"Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318:2019\u20132032","journal-title":"JAMA"},{"key":"2510_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.16677","volume":"35","author":"TV Nguyen","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LV et al (2021) Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 35:50\u201361","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2510_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ (2020) Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 82:1045\u20131058","journal-title":"J Am Acad Dermatol"},{"key":"2510_CR4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.2340\/00015555-2176","volume":"95","author":"N Vlassova","year":"2015","unstructured":"Vlassova N, Kuhn D, Okoye GA (2015) Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol 95:990\u2013991","journal-title":"Acta Derm Venereol"},{"key":"2510_CR5","first-page":"44","volume":"109","author":"NS Udechukwu","year":"2017","unstructured":"Udechukwu NS, Fleischer AB (2017) Higher risk of care for hidradenitis suppurativa in African American and non-hispanic patients in the United States. J Natl Med Assoc 109:44\u201348","journal-title":"J Natl Med Assoc"},{"key":"2510_CR6","doi-asserted-by":"crossref","first-page":"13030\/qt9xc0n0z","DOI":"10.5070\/D3236035391","volume":"23","author":"T Vaidya","year":"2017","unstructured":"Vaidya T, Vangipuram R, Alikhan A (2017) Examining the race-specific prevalence of hidradenitis suppurativa at a large academic center; results from a retrospective chart review. Dermatol Online J 23:13030\/qt9xc0n0z1","journal-title":"Dermatol Online J"},{"key":"2510_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000504911","volume":"237","author":"KN Price","year":"2021","unstructured":"Price KN, Hsiao JL, Shi VY (2021) Race and ethnicity gaps in global hidradenitis suppurativa clinical trials. Dermatology 237:97\u2013102","journal-title":"Dermatology"},{"key":"2510_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjd.19468","volume":"184","author":"VD Reddy","year":"2021","unstructured":"Reddy VD, Myers BA, Chan SY et al (2021) A review of current phase III clinical trials of plaque psoriasis: under-representation of nonwhite participants and need for reform. Br J Dermatol 184:348\u2013350","journal-title":"Br J Dermatol"},{"key":"2510_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J et al (2017) Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 153:760\u2013764","journal-title":"JAMA Dermatol"},{"key":"2510_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000486741","volume":"233","author":"DE Lee","year":"2017","unstructured":"Lee DE, Clark AK, Shi VY (2017) Hidradenitis suppurativa: disease burden and etiology in skin of color. Dermatology 233:456\u2013461","journal-title":"Dermatology"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-022-02510-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T21:21:39Z","timestamp":1701552099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-022-02510-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2510"],"URL":"https:\/\/doi.org\/10.1007\/s00403-022-02510-4","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tina Bhutani is a principal investigator for trials sponsored by Abbvie, Castle, CorEvitas, Dermavant, Galderma, Mindera, and Pfizer. She has received research grant funding from Novartis and Regeneron. She has been an advisor for Abbvie, Arcutis, Boehringer-Ingelheim, Bristol Myers Squibb, Janssen, Leo, Lilly, Novartis, Pfizer, Sun, and UCB. Wilson Liao has received research grant funding from Abbvie, Amgen, Janssen, Leo, Novartis, Pfizer, Regeneron, and TRex Bio. The remaining authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}}]}}